Q-omics provides the consensus-scored SSXP9 profile across patient tissues and cancer cell-line models. SSXP9 expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in TGCT. Among the 18 cancer types available for tumor–normal comparison, SSXP9 is differentially expressed in 1, with the highest sampling consensus in THCA. Additionally, SSXP9 RNA expression shows 9,603 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight TGCT, THCA, and COAD as cancer lineages where SSXP9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SSXP9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SSXP9 survival associations across molecular data types. SSXP9 RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SSXP9 RNA expression–survival associations across cancer types. High SSXP9 expression shows unfavorable associations in TGCT, UVM, LUSC, HNSC, UCS and GBM. The TGCT Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify TGCT as the clearest survival context for SSXP9 RNA expression.
This table summarizes SSXP9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for SSXP9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SSXP9 shows lower tumor expression in THCA. The THCA box plot shows higher SSXP9 RNA expression in normal versus tumor tissue (log2 FC = −0.043, t-test p = .039).
This table shows molecular features associated with SSXP9 in patient tissues and cancer cell lines. In patient samples, SSXP9 shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set.
